HK1208880A1 - Method for producing monomeric and multimeric molecules and uses thereof - Google Patents

Method for producing monomeric and multimeric molecules and uses thereof

Info

Publication number
HK1208880A1
HK1208880A1 HK15109566.8A HK15109566A HK1208880A1 HK 1208880 A1 HK1208880 A1 HK 1208880A1 HK 15109566 A HK15109566 A HK 15109566A HK 1208880 A1 HK1208880 A1 HK 1208880A1
Authority
HK
Hong Kong
Prior art keywords
multimeric molecules
producing monomeric
monomeric
producing
multimeric
Prior art date
Application number
HK15109566.8A
Other languages
English (en)
Chinese (zh)
Inventor
Johannes Auer
Martin Bader
Stefan Dengl
Stefan Lorenz
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1208880A1 publication Critical patent/HK1208880A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
HK15109566.8A 2012-08-02 2015-09-29 Method for producing monomeric and multimeric molecules and uses thereof HK1208880A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179021 2012-08-02
PCT/EP2013/066096 WO2014020069A1 (en) 2012-08-02 2013-07-31 Method for producing monomeric and multimeric molecules and uses thereof

Publications (1)

Publication Number Publication Date
HK1208880A1 true HK1208880A1 (en) 2016-03-18

Family

ID=48914281

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109566.8A HK1208880A1 (en) 2012-08-02 2015-09-29 Method for producing monomeric and multimeric molecules and uses thereof

Country Status (13)

Country Link
US (3) US20150218250A1 (es)
EP (1) EP2880169B1 (es)
JP (1) JP6388581B2 (es)
KR (1) KR20150037959A (es)
CN (1) CN104508133B (es)
BR (1) BR112015002091A2 (es)
CA (1) CA2876099A1 (es)
ES (1) ES2633894T3 (es)
HK (1) HK1208880A1 (es)
MX (1) MX2015000683A (es)
RU (1) RU2015106812A (es)
SG (1) SG11201408530YA (es)
WO (1) WO2014020069A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
AR101202A1 (es) * 2014-07-15 2016-11-30 Astellas Pharma Inc Anticuerpo anti-tie2 humana
CN107074966A (zh) * 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
CN114272901A (zh) * 2016-08-01 2022-04-05 株式会社钟化 钙蛋白粒子的吸附材料以及吸附除去系统及其利用方法
CA3033475A1 (en) 2016-08-10 2018-02-15 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
IL297617B2 (en) * 2016-12-22 2023-11-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
WO2019057180A1 (en) 2017-09-25 2019-03-28 Dingfu Biotarget Co., Ltd. PROTEIN HETÉRODIMÈRE AND USE THEREOF
CA3098374A1 (en) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
MX2021004711A (es) 2018-10-23 2021-07-02 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fragmento cristalizable (fc).
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
JP2023538902A (ja) * 2020-08-19 2023-09-12 ヤンセン バイオテツク，インコーポレーテツド 操作されたリガンドを使用する材料及び方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
CA2338000C (en) 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
BR0007414A (pt) * 1999-01-07 2001-10-16 Lexigen Pharm Corp Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1200124B1 (en) * 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
CZ20032208A3 (cs) 2001-02-23 2004-01-14 Immunex Corporation Zvýšený výtěžek aktivních proteinů
EP1516054B1 (de) * 2002-02-10 2009-12-02 Topotarget Switzerland SA Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
EP2027151A2 (en) * 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
WO2010048313A2 (en) 2008-10-22 2010-04-29 Biogen Idec Ma Inc. Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP3590965A1 (en) * 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
WO2012146630A1 (en) * 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof

Also Published As

Publication number Publication date
US20170342128A1 (en) 2017-11-30
JP2015531591A (ja) 2015-11-05
BR112015002091A2 (pt) 2017-12-12
CA2876099A1 (en) 2014-02-06
US20150218250A1 (en) 2015-08-06
RU2015106812A (ru) 2016-09-27
US10570188B2 (en) 2020-02-25
CN104508133B (zh) 2018-04-20
MX2015000683A (es) 2015-04-10
US11254728B2 (en) 2022-02-22
WO2014020069A1 (en) 2014-02-06
JP6388581B2 (ja) 2018-09-12
US20200157183A1 (en) 2020-05-21
CN104508133A (zh) 2015-04-08
EP2880169A1 (en) 2015-06-10
ES2633894T3 (es) 2017-09-25
KR20150037959A (ko) 2015-04-08
SG11201408530YA (en) 2015-03-30
EP2880169B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
HK1208880A1 (en) Method for producing monomeric and multimeric molecules and uses thereof
IL281148A (en) New and used KIF5B-RET fusion compounds
HK1214831A1 (zh) 新型融合分子及其應用
HK1206041A1 (en) Methods and means for the production of ig-like molecules
HK1210189A1 (en) Method for the production and selection of molecules comprising at least two different entities and uses thereof
ZA201406671B (en) Multispecific antigen-binding molecules and uses thereof
EP2931319A4 (en) MODIFIED NUCLEIC ACID MOLECULES AND THEIR USES
IL234234B (en) 2ang binding molecules
EP2814865A4 (en) PROCESS FOR PRODUCING POLYMER AND POLYMER PRODUCT
EP2918694A4 (en) STEEL ELEMENT AND PROCESS FOR PRODUCING THE SAME
EP2871482A4 (en) MICROCHIP AND METHOD FOR PRODUCING THE SAME
ZA201503542B (en) Novel immunotherapeutic molecules and uses thereof
ZA201405063B (en) Sealed-edge mirror and method for production thereof
EP2925777A4 (en) MONOLITH-BASED PSEUDO BIOAFFINITY CLEANING PROCEDURES FOR FACTOR VIII AND APPLICATIONS THEREOF
GB201213778D0 (en) Process and dressng
GB201218715D0 (en) Novel method and products
GB201208146D0 (en) Method and product